Details for Patent: 9,272,044
✉ Email this page to a colleague
Which drugs does patent 9,272,044 protect, and when does it expire?
Patent 9,272,044 protects SUBLOCADE and is included in one NDA.
This patent has forty-three patent family members in thirty countries.
Summary for Patent: 9,272,044
| Title: | Injectable flowable composition buprenorphine |
| Abstract: | The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis. |
| Inventor(s): | Norton; Richard L. (Fort Collins, CO), Watkins; Andrew (Fort Collins, CO), Zhou; Mingxing (Fort Collins, CO) |
| Assignee: | Indivior UK Limited (Slough, GB) |
| Application Number: | 14/610,818 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,272,044 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Device; |
More… ↓ |
Drugs Protected by US Patent 9,272,044
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indivior | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE | ⤷ Subscribe | ||||
| Indivior | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH | ⤷ Subscribe | ||||
| Indivior | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE COMPOSITION WITH 28 DAY DOSE DURATION | ⤷ Subscribe | ||||
| Indivior | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATING OPIOID ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,272,044
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 1009549.5 | Jun 8, 2010 |
International Family Members for US Patent 9,272,044
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011263478 | ⤷ Subscribe | |||
| Brazil | 112012031290 | ⤷ Subscribe | |||
| Canada | 2801676 | ⤷ Subscribe | |||
| Chile | 2012003462 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
